Orphan Therapeutics Acquires Full Rights To Terlipressin From PDL BioPharma
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will initiate a rolling NDA submission in Q2 2007 despite failure to meet novel primary endpoint, Orphan president tells “The Pink Sheet” DAILY.
You may also be interested in...
Roche Backs Out Of Daclizumab Transplantation Deal With PDL
PDL is moving forward with Phase II development of the biologic in multiple sclerosis with partner Biogen Idec.
PDL Focus Remains Nuvion, But 2007 Could Include Several Significant Deals
The biotech is “aggressively” seeking potential in-licensing opportunities and hopes to partner its heart failure agent ularitide in 2007.
PDL’s Terlipressin Fails Phase III Trial; Company To Meet With FDA
Late-stage development compound was evaluated for treatment of type 1 hepatorenal syndrome.